Blockchain Registration Transaction Record

Soligenix Expands European Advisory Board for CTCL Treatment

Soligenix expands European Medical Advisory Board to advance HyBryte treatment for Cutaneous T-cell lymphoma. First-in-class photodynamic therapy addresses unmet medical need in rare cancer treatment.

This development matters because Cutaneous T-cell lymphoma represents a significant unmet medical need with limited treatment options, particularly for early-stage patients. The advancement of HyBryte could establish a new standard of care for a rare but serious condition affecting millions globally. For patients suffering from CTCL, this represents potential access to a first-in-class therapy that may offer better outcomes and improved quality of life. The European expansion also signals growing international recognition of this innovative treatment approach, potentially accelerating regulatory approvals and patient access across multiple markets. In the broader context of rare disease treatment, successful development of HyBryte could demonstrate the viability of photodynamic therapies for other challenging medical conditions.